Clinical Trial

A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors

Name: A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors — clinical trial record (NCT07229612)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-13

Trial Details

NCT Number	NCT07229612
Lead Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Malignant Solid Tumors
Enrollment	200 participants
Start Date	2025-12-03
Primary Completion	2028-11 (estimated)
Study Completion	2028-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-12